Veralipride
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 326876

CAS#: 66644-81-3

Description: Veralipride is a benzamide neuroleptic medicine indicated in the treatment of vasomotor symptoms associated with the menopause. It was first authorised for use in 1979. Veralipride was withdraw from the market in 2007.


Chemical Structure

img
Veralipride
CAS# 66644-81-3

Theoretical Analysis

MedKoo Cat#: 326876
Name: Veralipride
CAS#: 66644-81-3
Chemical Formula: C17H25N3O5S
Exact Mass: 383.1515
Molecular Weight: 383.463
Elemental Analysis: C, 53.25; H, 6.57; N, 10.96; O, 20.86; S, 8.36

Price and Availability

Size Price Availability Quantity
2.0mg USD 330.0 2 Weeks
25.0mg USD 1650.0 2 Weeks
Bulk inquiry

Synonym: LIR 1660, LIR-1660, LIR1660, Veralipride, Agreal, Agradil

IUPAC/Chemical Name: N-((1-allylpyrrolidin-2-yl)methyl)-2,3-dimethoxy-5-sulfamoylbenzamide

InChi Key: RYJXBGGBZJGVQF-UHFFFAOYSA-N

InChi Code: InChI=1S/C17H25N3O5S/c1-4-7-20-8-5-6-12(20)11-19-17(21)14-9-13(26(18,22)23)10-15(24-2)16(14)25-3/h4,9-10,12H,1,5-8,11H2,2-3H3,(H,19,21)(H2,18,22,23)

SMILES Code: O=C(NCC1N(CC=C)CCC1)C2=CC(S(=O)(N)=O)=CC(OC)=C2OC

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 383.463 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Valencia MH, Arias Mde J, González CC, Marín IH, González JH, Campos ER, Rodríguez MA, Álvarez IM, Vargas MA, Flores JB, Haro SS, Bonilla MC, Escudero RB, Campero RA. Safety of veralipride for the treatment of vasomotor symptoms of menopause. Menopause. 2014 May;21(5):484-92. doi: 10.1097/GME.0b013e3182a46dcb. PubMed PMID: 24065139.

2: Basavilvazo-Rodríguez A, Bravo-Rodríguez LM, Carranza-Lira S, Celis-González C, Hernández Marín I, Hernández-Valencia M, López Navarro ME, Alvarado Maldonado Jde D, Armando Montaño J, Moreno Avellán AJ, Vázquez G. [Consensus conference of the Mexican Association for the Study of Climateric on veralipride prescription for patients with vasomotor symptoms]. Ginecol Obstet Mex. 2012 Jul;80(7):467-72. Spanish. PubMed PMID: 22916640.

3: Martí Massó JF, Ruiz-Martínez J, Bergareche A, López de Munain A. [Parkinsonism induced by sulpiride and veralipride: two different stories]. Med Clin (Barc). 2011 Oct 15;137(10):473-4. doi: 10.1016/j.medcli.2010.09.038. Epub 2011 Feb 4. Spanish. PubMed PMID: 21295788.

4: Carranza-Lira S. Actual status of veralipride use. Clin Interv Aging. 2010 Sep 7;5:271-6. Review. PubMed PMID: 20852674; PubMed Central PMCID: PMC2938034.

5: Carretti N, Florio P, Reis FM, Comai S, Bertazzo A, Petraglia F. Reduction of serum serotonin precursors after veralipride treatment for postmenopausal hot flushes. Climacteric. 2010 Apr;13(2):141-6. doi: 10.3109/13697130903219208. PubMed PMID: 20082603.

6: Alonso-Navarro H, Jiménez-Jiménez FJ. Tardive blepharospasm beginning after withdrawal of veralipride. Mov Disord. 2006 Nov;21(11):2033-4. PubMed PMID: 16960858.

7: Montemurro D, Rossi GP. Veralipride-induced acute coronary syndrome unmasking a non-secreting pheochromocytoma. J Endocrinol Invest. 2006 Jul-Aug;29(7):650-2. PubMed PMID: 16957415.

8: De Leo V, Morgante G, Musacchio MC, Faldini E, Delia A, Petraglia F. The safety of veralipride. Expert Opin Drug Saf. 2006 Sep;5(5):695-701. Review. PubMed PMID: 16907659.

9: Raja M, Azzoni A. Tardive dyskinesia after long-term veralipride treatment. J Neuropsychiatry Clin Neurosci. 2005 Spring;17(2):252-3. PubMed PMID: 15939983.

10: Masmoudi K, Gras-Champel V, Lemaire-Hurtel AS, Masson H, Munier A, Geslin JM, Andréjak M. [Extrapyramidal adverse effects of veralipride (Agreal), a drug used to treat hot flushes: a propos of 17 cases]. Rev Med Interne. 2005 Jun;26(6):453-7. Epub 2005 Mar 17. French. PubMed PMID: 15936474.

11: Morgante G, Farina M, Cianci A, La Marca A, Petraglia F, De Leo V. Veralipride administered in combination with raloxifene decreases hot flushes and improves bone density in early postmenopausal women. Gynecol Endocrinol. 2004 Apr;18(4):194-8. PubMed PMID: 15293890.

12: Teive HA, Sa DS. Worsening of Parkinsonism after the use of veralipride for treatment of menopause: case report. Arq Neuropsiquiatr. 2001 Mar;59(1):123-4. PubMed PMID: 11299446.

13: Marta-Moreno E, Gracia-Naya M, Marzo-Sola ME. [Respiratory dyskinesia induced by veralipride]. Rev Neurol. 1997 Feb;25(138):245-7. Spanish. PubMed PMID: 9147748.

14: Masmoudi K, Decocq G, Chetaille E, Rosa A, Mizon JP, Andréjak M. [Extrapyramidal disorders induced by veralipride (Agreal). Apropos of 5 cases]. Therapie. 1995 Sep-Oct;50(5):451-4. French. PubMed PMID: 8571284.

15: Franchignoni FP, Tesio L. [Parkinson syndrome induced by veralipride]. Minerva Ginecol. 1995 Jun;47(6):277-9. Italian. PubMed PMID: 7478098.

16: Vercellini P, Sacerdote P, Trespidi L, Manfredi B, Panerai AE, Crosignani PG. Veralipride for hot flushes induced by a gonadotropin-releasing hormone agonist: a controlled study. Fertil Steril. 1994 Nov;62(5):938-42. PubMed PMID: 7926138.

17: Staveris S, Houin G, Dufour A, Plusquellec Y, Grenier JF, Jung L, Koffel JC, Saivin S. Evidence for a second site of absorption of veralipride in the human small intestine. Use of a new drug delivery telemetric shuttle. Arzneimittelforschung. 1994 Sep;44(9):1068-72. PubMed PMID: 7986246.

18: Iruela LM, Caballero L, Ibánez-Rojo V, Palanca I. Panic-like symptoms after veralipride withdrawal. J Clin Psychiatry. 1993 Dec;54(12):488-9. PubMed PMID: 8276741.

19: Gabellini AS, Pezzoli A, De Massis P, Sacquegna T. Veralipride-induced tardive dystonia in a patient with bipolar psychosis. Ital J Neurol Sci. 1992 Oct;13(7):621-3. PubMed PMID: 1428799.

20: Vercellini P, Vendola N, Colombo A, Passadore C, Trespidi L, Crosignani PG. Veralipride for hot flushes during gonadotropin-releasing hormone agonist treatment. Gynecol Obstet Invest. 1992;34(2):102-4. PubMed PMID: 1398260.